Current Opinion in Chemical Biology · Nov 12, 2026

Genome engineering with base editors: Technological advancements enabling clinical translation

By Anderson RA, Komor AC

Base editors (BEs) are precision genome editing tools which allow for the efficient introduction of point mutations in live cells without using double-strand DNA breaks. The two main classes of BEs are cytosine base editors (CBEs) and adenine base editors (ABEs), which can introduce C•G to T•A and A•T to G•C mutations, respectively. Since their development, BEs have been further developed and improved to address issues related to efficiency, specificity, and precision. In this review, we briefly summarize several recent notable developments in the field relevant to their path to the clinic, as well as three clinical trials from the past three years which apply BEs to the treatment of T-cell acute lymphoblastic leukemia, hypercholesterolemia, and a rare N = 1 urea cycle disorder. In these examples, base editing is used to precisely knock out genes or correct mutations back to wild-type in blood disorders and liver diseases. Through clinical trials, patients around the world are being treated with BE therapeutics, ushering in the next generation of precision medicine.

doi.org/10.1016/j.cbpa.2026.102813Open accessPubMed 43044265Interventions

AgingResearch.News